Researchers examined trends in adherence to various treatment among patients with psoriasis using data from a large health insurance database. For which therapy had the highest odds for adherence, read more.
Thursday, July 7, 2016
Families with a history of cardiovascular disease increase the risk of first-time major adverse cardiovascular events occurring in young adults with psoriasis.
Monday, June 27, 2016
Psoriasis patients, treated with ixekizumab (Taltz), experienced short- and long-term improvements in work productivity that could lead to a reduced productivity-related cost burden, according to a new study published online in JAMA Dermatology.
Friday, June 10, 2016
Results from 3 Phase 3 studies, published in The New England Journal of Medicine, demonstrated the safety and efficacy of ixekizumab (Taltz) for the treatment of moderate to severe plaque psoriasis.